Ginkgo and Aldevron tout mRNA manufacturing ‘breakthrough’—and the perks could stretch well beyond COVID-19, exec says
A multibillion-dollar SPAC deal? Check. An international acquisition? Check. An mRNA vaccine production "breakthrough?" Ginkgo Bioworks says it has that, too.
With i...
Continue Reading →
